| 1.01 -0.03 (-2.88%) | 02-20 15:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.09 | 1-year : | 1.28 |
| Resists | First : | 0.93 | Second : | 1.09 |
| Pivot price | 0.88 |
|||
| Supports | First : | 0.87 | Second : | 0.83 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 0.88 |
| MA(100) : | 0.91 |
MA(250) : | 1.28 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 48.9 |
| RSI | RSI(14): 52.2 | |||
| 52-week | High : | 2.79 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HOOK ] has closed below upper band by 27.3%. Bollinger Bands are 69.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 79 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.91 | 0.91 - 0.91 |
| Low: | 0.88 - 0.88 | 0.88 - 0.89 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Wed, 04 Feb 2026
HOOKIPA Pharma T0 Sell Oncology Assets HB-200 And HB-700 To NeoTrail Therapeutics - Nasdaq
Tue, 03 Feb 2026
HOOKIPA Pharma Sells Oncology Assets To NeoTrail Therapeutics - citybiz
Tue, 03 Feb 2026
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics - Sahm
Tue, 03 Feb 2026
NeoTrail picks up HOOKIPA’s next-gen cancer vaccines in undisclosed deal - Stock Titan
Tue, 03 Feb 2026
HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail Therapeutics - Quiver Quantitative
Fri, 31 Oct 2025
HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 131 (K) |
| EPS | -5.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.71 |
| Profit Margin | 0 % |
| Operating Margin | -885.3 % |
| Return on Assets (ttm) | -45.3 % |
| Return on Equity (ttm) | -105.8 % |
| Qtrly Rev. Growth | -94.5 % |
| Gross Profit (p.s.) | -5.09 |
| Sales Per Share | 0.94 |
| EBITDA (p.s.) | -7.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0.94 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|